GLP-3 RT
Triple GIP / GLP-1 / Glucagon Agonist
- Form
- Lyophilized powder
- Storage
- -20°C (lyophilized)
- Origin
- USA lab
from$119
GLP-3 RT is a synthetic peptide reference material used in laboratory investigations of GIP, GLP-1, and glucagon receptor activity and multi-receptor signaling.
- GIP, GLP-1, and glucagon receptor research
- Multi-receptor activation studies
- In-vitro metabolic signaling models
SKU: AP-RETA-10MG
3 vial minimum per order — mix any products
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
Reconstitution ReferenceOptional — how strong is the mixed vial?
Mixing a powder vial with water? Fill in the fields — results update as you type.
Mixing 10 mg of peptide into 2 mL of water makes a 5 mg/mL solution. Each 0.1 mL contains 0.5 mg.
Reference for in-vitro laboratory handling only. Outputs describe the physical properties of the reconstituted vial (concentration and mass drawn) — they are not dosing guidance, administration instructions, or medical advice. Verify all measurements independently.
The science behind GLP-3 RT
A structured overview of the published literature surrounding the triple-receptor agonist studied here as GLP-3 RT.
GLP-3 RT (retatrutide) is a synthetic peptide engineered to engage three receptors — the GIP, GLP-1, and glucagon receptors. It is studied as a triple-agonist reference compound in metabolic-signaling research.
As one of the newer multi-receptor incretin compounds, it appears in receptor-pharmacology assays and preclinical models exploring how triple-receptor engagement compares with dual- and single-agonist profiles.
The material supplied here is intended solely as a laboratory reference standard, and the summaries below describe only findings reported in published research.
The compound emerged from research into multi-receptor incretin agonists, extending the dual-agonist concept by adding glucagon-receptor engagement to GIP and GLP-1 activation.
It is characterized in an emerging body of receptor-pharmacology and preclinical metabolic literature and is used as a comparator in triple-agonist research.
The mechanism of interest is simultaneous agonism at the GIP, GLP-1, and glucagon receptors, with reported activation of cAMP-dependent signaling across cellular models expressing each receptor.
Researchers examine how adding glucagon-receptor activity to incretin agonism influences downstream metabolic-signaling profiles in preclinical systems.
Triple-receptor assays
Used to characterize GIP, GLP-1, and glucagon receptor activation within one reference compound.
Incretin signaling
Examined in cellular cAMP and metabolic-signaling models.
Energy-metabolism models
Referenced in preclinical research on energy expenditure and glucose regulation.
Comparative pharmacology
Studied alongside dual and single agonists to characterize triple-agonism signatures.
What is GLP-3 RT?
A synthetic triple GIP/GLP-1/glucagon receptor agonist peptide (retatrutide) supplied as a laboratory reference material for receptor-signaling research.
What kind of research references it?
Receptor-pharmacology assays and preclinical metabolic models exploring triple-receptor activation.
Is GLP-3 RT approved for human or veterinary use?
No. GLP-3 RT is not approved by the FDA or any regulatory authority for human or animal use. It is sold exclusively for in-vitro and laboratory research and is not for consumption.
How is the reference material characterized?
Each released lot is supplied as a lyophilized powder with a lot-specific certificate of analysis reporting HPLC purity of ≥ 99%. The certificate is tied to the specific released lot.
How should the compound be stored?
Lyophilized material is typically stored at -20°C, protected from light and moisture. Handling should follow standard laboratory practice for peptide reference materials. We do not provide reconstitution, dosing, or administration guidance.
- Coskun T, et al. LY3437943, a novel GIP, GLP-1 and glucagon receptor triagonist. Cell Metab (2022).
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med (2023).
Links open a curated peer-reviewed search on PubMed. Allpointe Bio Research is not affiliated with the cited authors or publishers.
Research-Use Statement
The information above is provided for educational and scientific-reference purposes only and summarizes findings reported in the published preclinical and in-vitro literature. It is not medical advice and does not describe outcomes, benefits, or applications for humans or animals. GLP-3 RT is supplied strictly as a laboratory reference material for in-vitro and research use only — it is not a drug or supplement, is not approved for human or veterinary use, and is not for consumption. Allpointe Bio Research does not provide clinical, dosing, reconstitution, or administration guidance.